What are the normal parameters of the menstrual cycle and the recommended management for dysmenorrhea and heavy menstrual bleeding in a healthy adult woman?

Menstruation: Normal Parameters and Management

Normal Menstrual Cycle Parameters

A normal menstrual cycle ranges from 21-35 days, with menstrual flow lasting 2-7 days. Heavy menstrual bleeding (HMB) is defined as blood loss exceeding 80 mL per cycle or bleeding that interferes with physical, emotional, and social wellbeing 1. Practical indicators of HMB include clots ≥1 inch diameter, "flooding" (changing pad/tampon more than hourly), or prolonged menses beyond 7 days 2.

Management of Dysmenorrhea

Primary Dysmenorrhea

For primary dysmenorrhea (menstrual pain without pelvic pathology), NSAIDs are the first-line treatment, with hormonal contraceptives as an equally effective alternative 3, 4. The key advantage is that treatment can begin immediately without requiring pelvic examination or invasive procedures 4.

Treatment Algorithm:

• First-line options:

  • NSAIDs during days of pain (typically 5-7 days)
  • Combined hormonal contraceptives (oral, patch, or ring)
  • Progestin-only contraceptives

• Adjunctive therapies: Topical heat and exercise provide additional benefit 3

• Red flags requiring further investigation:

  • Abnormal uterine bleeding patterns
  • Dyspareunia (painful intercourse)
  • Non-cyclic pain
  • Changes in pain intensity/duration
  • Abnormal pelvic examination findings

These red flags suggest secondary dysmenorrhea (underlying pathology like endometriosis or adenomyosis) and warrant transvaginal ultrasonography 3.

Critical Pitfall

Do not delay treatment while pursuing a definitive diagnosis 4. Untreated persistent menstrual pain may develop into chronic pain syndrome. Treatment should be initiated based on clinical presentation alone.

Management of Heavy Menstrual Bleeding

Initial Assessment

Before treatment, evaluate for:

• Pregnancy (always rule out first)
• Anemia (check hemoglobin at least once) 5
• Underlying bleeding disorders (especially if HMB accompanied by personal/family bleeding history, flooding, or prolonged menses) 2, 6
• Structural abnormalities via transvaginal ultrasound 5
• Thyroid dysfunction and hyperprolactinemia 7

Up to 20% of women with HMB have an underlying inherited bleeding disorder 1, making hematology referral essential when HMB presents with flooding, prolonged menses, or positive bleeding history 2.

Medical Management Hierarchy

The levonorgestrel-releasing intrauterine system (LNG-IUS, 20 μg/24 hours) is the single most effective first-line medical treatment for HMB 8, 5. This recommendation is based on superior efficacy in reducing menstrual blood loss (71-95% reduction) compared to all other medical options 9, 8.

Treatment Algorithm by Effectiveness (Descending Order):

1. LNG-IUS (20 μg/24 hours) - First choice 8, 5

   • Most effective for endometrial dysfunction
   • Also effective for HMB due to fibroids and adenomyosis
   • Comparable efficacy to endometrial ablation

2. Combined hormonal contraceptives - Second choice 8

   • Oral, transdermal patch, or vaginal ring
   • Short-term treatment: 10-20 days during bleeding episodes 10

3. Tranexamic acid - Third choice 8

   • Hemostatic therapy, particularly useful when hormonal options contraindicated
   • Caution: Should generally be avoided in women with cardiovascular disease risk, including those with history of spontaneous coronary artery dissection (SCAD) 9

4. Long-course oral progestogens - Fourth choice 8

   • ≥3 weeks per cycle
   • Less effective than above options

5. NSAIDs - Limited efficacy 8

   • Short-term treatment (5-7 days) 10
   • Reduces blood loss but less impressively than hormonal options
   • May be sufficient for marginally increased blood loss

Management of Bleeding Irregularities on Contraception

When women experience unscheduled bleeding while using contraception, first rule out underlying gynecological problems: medication interactions, STDs, pregnancy, or new pathologic uterine conditions (polyps, fibroids) 10.

If no underlying problem is found and treatment is desired:

For spotting or light bleeding:

• NSAIDs for 5-7 days 10

For heavy or prolonged bleeding:

• NSAIDs for 5-7 days, OR
• Hormonal treatment (if medically eligible): low-dose COCs or estrogen for 10-20 days 10

For amenorrhea:

• Reassurance only - no medical treatment needed 10
• Rule out pregnancy if bleeding pattern changes abruptly to amenorrhea

When Medical Management Fails

If medical treatment fails, is contraindicated, not tolerated, or if significant intracavitary lesions are present, surgical options include endometrial ablation (second-generation techniques preferred) or hysterectomy 7, 1, 5.

For HMB with uterine fibroids specifically, uterine artery embolization is a good alternative to hysterectomy 5.

Special Populations

Adolescents with HMB: There is substantial diagnostic delay in identifying underlying bleeding disorders in this population 6. Maintain high index of suspicion and refer to hematology when appropriate, as missed diagnosis results in significant morbidity and risk with future hemostatic challenges.

Women on antiplatelet therapy (post-SCAD): When HMB develops, first reassess indication for ongoing antiplatelet therapy and discontinue if appropriate 9. The levonorgestrel 20 μg/d-releasing IUD is particularly useful in this setting, as it controls bleeding locally with minimal systemic absorption 9. Avoid tranexamic acid and NSAIDs due to thrombosis/MI risk 9.

Quality of Life Impact

HMB and dysmenorrhea severely impact quality of life, causing physical symptoms (pelvic pain, sleep issues, mood disturbance), impaired academic performance, and restricted daily activities 11, 12. Over 80% of young women with these conditions experience significant physical and psychological problems 11. This underscores the importance of prompt, effective treatment rather than dismissing symptoms as "normal" menstrual complaints.